Seeking Alpha


Send Message
View as an RSS Feed
View rlbeard's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead: A Much Bigger Story Than Just Sovaldi [View article]
    GILD makes up 65% of my portfolio counting the options that I own. I own jan 15 $40 calls that I bought in jan of this year at $36 with the intention of converting them to stock in jan 15 but the premium was so low that it was less than 3.5% interest. I too believe that it will hit 125 or more by this time next year. They are not standing still but still producing drugs that will outpace competition. Sales will continue to rise but so will prescription insurance premiums. Medicare part D will go up $5 per month next year and Obama will frown and say it is not his fault but the greedy republican drug companies.
    Aug 5 09:30 PM | Likes Like |Link to Comment
  • A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval [View article]
    I want to thank you for including Idealisib in your analysis, it has seemed to be ignored by the market and I really wanted to see some analysis on the projected sales. thanks again.
    Jul 24 07:28 PM | 1 Like Like |Link to Comment
  • Understanding The Excitement That Surrounds Gilead [View article]
    I have been looking for a GILD article that projects what the stockholders can expect out of Idealisib that was just approved. I find it hard to believe that this has gone almost entirely unnoticed. This drug will add greatly to earnings and yet it is swept under the rug by stockholders and analysts. I really would like to see a serious discussion about Gild and this new drug and nothing else
    Jul 24 07:19 PM | 5 Likes Like |Link to Comment
  • Gilead Results Can Affect The Entire Market [View article]
    are you enjoying the crow pie ?? what a huge mistake in this article and your choice. This even exceeded my $1.20 estimate of earnings. It was huge and will continue and the chart channel is definitely intact and it is up
    Apr 22 04:26 PM | Likes Like |Link to Comment
  • Gilead Results Can Affect The Entire Market [View article]
    I think you have missed the whole consensus on this stock and this article is like one written on AAPL when it was at $85 but kept going til it hit $700. The drug is the best selling drug of all time and the PE doesnt reflect that yet and the pipeline is huge esp Idealisib. You need ot take off your rose colored glasses, you may trade well but investing is another story. The fact it went to 64 and now back to 72 AH tells me you have already missed out on a lot of gain because of those glasses.
    Apr 21 06:30 PM | 2 Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    you are a fraud and the $15 million didnt happen and wont, it was a made up number by you, so do your DD before you write another article with fabricated numbers or state it is your opinion and not fact.
    Apr 12 06:04 PM | 2 Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    every comment a bout the company you stated I believe as a substantial stock holder but that is not the point, It was not stated as an opinion, it was stated as a material fact that was not true and had no source. It was misleading and fraudulent imo. The author was not suppose to be writing fiction, he did not say I believe they will get $15 million, he stated that was the agreement.
    Apr 12 06:01 PM | 1 Like Like |Link to Comment
  • Mast Pharmaceuticals Inc.: Breakthrough Drug MST-188 Could Lead To Huge Gains [View article]
    I would suggest that if you follow this author that you do so with great care as has been porven on his article on IPCI his numbers are some times fictional and he is not willing to provide links for his statements so one has to assume they are false or fictitious. So I would do a lot of DD before I put too much credence in any of his articles, Even though a complaint was filed with SA they continue to let him post articles I do not read them any more since he has been porven not to be willing to support his facts.
    Feb 1 02:44 PM | 1 Like Like |Link to Comment
  • Gilead: The Rising Tide Is Coming [View article]
    the smart move would be to sell at 84 and buy back at 74 but what makes you think it will go back to 74?? What if it keeps going up and never comes back down? There is a possiblility that will happen but looking at the one year chart when did it correct 16% before. If it did that people would be saying a head and shoulders formed and you should not get back in. Chartists are hypothetical and should be used for support and resistance points and not for fact that you will see them IMO. gl
    Jan 22 08:04 AM | 1 Like Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    I spoke with the company also and was told flat out that there was no $15 million fee that if I checked with the company that bought Par their fillings would show that amount to be much less that was set aside as stated by a poster previously in the $3 to $4 million range. The person I spoke to also stated the company has never issued a press release on the amount as it is confidential and not being disclosed. When Bob non chalantly says do your own DD he is covering his rear end as he can not point to anything to prove his statement. It is my personal belief than most of his article is to pump and dump this stock at the time of the article. His failure to substantiate his comments have discredited him to me and caused me to file a complaint to SA. The fact that they have not responded in regards to this complaint and how they are handling it leads me to suspect that they too are culpable. Unless I get a decent response from them I will have a tendency to discredit most of their articles unless I can find articles by substantial outlets to verify and if I can do that why do I need to read them at all. I keep coming back here only to see if there is some response from Bob or SA to this fiasco.
    Dec 20 09:31 PM | 1 Like Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    when I complained to SA about this article they gave 3 immediate answers number 1 was that I could correct my problem by not reading their articles (paraphrased) but they did say correct it by unsubscribing to their alerts and articles. That is totally the wrong thing to say when they have an author that is publishing unverifiable statements and makes them culpable. I am sure it is a blanket statement along with the other two suggestions but it is uncalled for.imo
    Dec 12 01:12 PM | 1 Like Like |Link to Comment
  • Chelsea Therapeutics: Primed For An Easy Double [View article]
    I have personally come to the conclusion that bob hides behind "do your own diligence" to cover his lies in articles that pump his stock so he can dump it to readers. He is going on my ignore what he says list and on my list to warn readers of his false claims in articles that he pumps. When called out he doesn't come up with support but attacks his posters in subtle ways. What a sham.
    Dec 12 09:09 AM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    thank you hike leader that is a good article and the first I have seen that matches what I was told at IPCI or alluded to not actually stated and was in that exact range and was told was published by the company you state. The only knowledgable statement out here so far. Bob needs to be censored by SA for his false reporting
    Dec 12 09:05 AM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    I have done my own DD and it is not anywhere and I have spoken to the company and they deny it and say it is not true. So it seems unless you can give proof that you lied and made up the numbers and your answer is a fake move to try to cover up your lies. So post the research where you got this or admit you made it up so you could profit. As in my opinion you should be barred from future publications on SA.
    Dec 12 08:58 AM | 1 Like Like |Link to Comment
  • Gilead Sciences: Sovaldi Hepatitis C Pill Approved [View article]
    an $11 Billion initial cost to buy it would be the first thought that came to mind and recouping that along with costs of carrying for a year, new studies, FDA application, lawyers supporting patent suits, other lawsuits etc. nothing is free except hep C and how you got it.
    Dec 10 07:01 AM | 1 Like Like |Link to Comment